Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
---|
06/24/2004 | WO2003053966A8 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
06/24/2004 | WO2003049686A3 Stabilization of hypoxia inducible factor (hif) alpha |
06/24/2004 | WO2002086075A3 Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
06/24/2004 | US20040122030 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide |
06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
06/24/2004 | US20040121993 for the reduction of cholesterol in blood, and treatment of fatty liver, hyperglycemia and diabetes |
06/24/2004 | US20040121962 Prodrugs of excitatory amino acids |
06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
06/24/2004 | US20040120948 antibody or a functional fragment thereof that recognizes a human CD40 antigen present on the surface of human B cells, dendritic cells |
06/24/2004 | CA2509242A1 Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
06/24/2004 | CA2508623A1 Benzomorpholine derivatives |
06/24/2004 | CA2507987A1 A vegetable composition having blood enhancing properties |
06/23/2004 | EP1431285A1 Reverse hydroxamic acid derivatives |
06/23/2004 | EP1430890A1 Thrombus/thrombogenesis inhibitors |
06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
06/23/2004 | EP1430140A2 Isoform-selective inhibitors and activators of pde3 cyclic |
06/23/2004 | EP1430067A2 Eukaryotic cells and method for preserving cells |
06/23/2004 | EP1430053A1 Chemical compounds |
06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
06/23/2004 | EP1429781A2 Composition comprising nanoparticulate spironolactone |
06/23/2004 | EP1429779A2 Androstanes as androgen receptor modulators |
06/23/2004 | EP1429754A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
06/23/2004 | EP1429617A2 Methods for sterilizing preparations of digestive enzymes |
06/23/2004 | EP1353906B1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
06/23/2004 | EP1342730A4 Fusion protein having the enhanced in vivo activity of erythropoietin |
06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
06/23/2004 | EP1071427B1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
06/23/2004 | EP0906340B1 Purification of factor viii complex by immunoaffinity chromatography |
06/23/2004 | CN1507450A Novel cyclo azaphospha hydrocarbons |
06/23/2004 | CN1507358A Carrier with solid fibrinogen and solid thrombin |
06/23/2004 | CN1507356A Remedies for sepsis |
06/23/2004 | CN1507352A Compound plant medicine and its application |
06/23/2004 | CN1506459A Lumbricus kinase of electrophoretical purity and its prepn and use |
06/23/2004 | CN1506109A Chinese medicine capsule for treating hemopathy and its prepn |
06/23/2004 | CN1506107A Chinese medicine for treatnig hemorrhagic diseases caused by reduced serozyme |
06/23/2004 | CN1506053A Cell growth regulating factor W and its prepn process |
06/23/2004 | CN1154729C Staphylokinase derivs |
06/23/2004 | CN1154650C Triazole-[4,5-d] pyrididines compound, its preparation, use and medical composition containing the same |
06/23/2004 | CN1154648C Stable crystal salt of 5-methyl tetrahydrofolic acid |
06/23/2004 | CN1154647C Imidazonephthyridines and their use in inducing cytokine biosynthesis |
06/23/2004 | CN1154490C Celecoxib compositions |
06/22/2004 | US6753332 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
06/22/2004 | US6753331 Heterocyclic derivatives which inhibit factor Xa |
06/22/2004 | CA2126241C Sulphated polysaccharide, preparation thereof, pharmaceutical composition and use thereof |
06/17/2004 | WO2004050636A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
06/17/2004 | WO2004050075A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
06/17/2004 | WO2004050074A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
06/17/2004 | WO2004012651A3 Composition for heart disease, method to prepare same and uses thereof |
06/17/2004 | WO2004003164A3 Methods of organ regeneration |
06/17/2004 | WO2003102138A3 Elongase genes and uses thereof |
06/17/2004 | WO2003070184A3 Sodium channel blockers |
06/17/2004 | WO2003053997A3 Methods of increasing endogenous erythropoietin (epo) |
06/17/2004 | WO2003051380A3 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
06/17/2004 | WO2003039341A3 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 |
06/17/2004 | WO2003017992A3 Means for treatment of atherosclerosis |
06/17/2004 | US20040116715 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
06/17/2004 | US20040116697 Novel compounds |
06/17/2004 | US20040116486 Metalloproteinase inhibitors |
06/17/2004 | US20040116440 Useful for diagnosis, treatment of male or female sexual dysfunction |
06/17/2004 | US20040116439 Serine protease inhibitors |
06/17/2004 | US20040116431 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
06/17/2004 | US20040116426 Small molecules useful in the treatment of inflammatory disease |
06/17/2004 | US20040116424 Aryl imidazoles and related compounds as C5a receptor modulators |
06/17/2004 | US20040116405 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
06/17/2004 | US20040116380 enhance a host's immune defense mechanisms to infection but do not induce an inflammatory response |
06/17/2004 | US20040116374 C2, 8-disubstituted adenosine derivatives and their different uses |
06/17/2004 | US20040116357 For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity |
06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
06/17/2004 | US20040116345 Novel albumin-free factor VIII formulations |
06/17/2004 | US20040116327 Administering compound capable of simultaneously binding PPAR alpha and PPAR gamma or concomitantly administering a compound that selectively binds PPAR alpha with a compound that selectively binds PPAR gamma to prevent rupture |
06/17/2004 | US20040115773 Serpin in bifidobacteria |
06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
06/17/2004 | CA2507750A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
06/17/2004 | CA2507624A1 Imidazole-derivatives as factor xa inhibitors |
06/16/2004 | EP1428883A1 Megakaryocyte stimulating factors |
06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
06/16/2004 | EP1427820A2 Modified factor ix |
06/16/2004 | EP1427811A1 Erythrocytic cells and method for preserving cells |
06/16/2004 | EP1427750A1 Modified transferrin fusion proteins |
06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
06/16/2004 | EP1427415A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
06/16/2004 | EP1268469B1 N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants |
06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
06/16/2004 | EP0960104B1 N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
06/16/2004 | EP0787003B1 Animal model system for the testing of drug candidates for the treatment of leukemia or hiv |
06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
06/16/2004 | CN1505619A Preparation of warfarin sodium from warfarin sodium 2-propanol clathrate by nondestructive solvent expulsion |